Spectral Diagnostics Inc.

Spectral Diagnostics Inc.

March 08, 2005 08:30 ET

Spectral Announces Updates on Corporate Launch Activities at the Clinical Laboratory Managers Association Meeting


NEWS RELEASE TRANSMITTED BY CCNMatthews

FOR: SPECTRAL DIAGNOSTICS INC.

TSX SYMBOL: SDI

MARCH 8, 2005 - 08:30 ET

Spectral Announces Updates on Corporate Launch
Activities at the Clinical Laboratory Managers
Association Meeting

TORONTO, ONTARIO--(CCNMatthews - March 8, 2005) - Spectral Diagnostics
Inc. (TSX:SDI) today announces the launch of its rapid test reader, the
i-Lynx at the Clinical Laboratory Managers Association (CLMA) meeting,
March 6-8, in Chicago, the largest meeting of Laboratory Directors in
the United States.

At this meeting Spectral will begin the United States launch of its
proprietary portable test reader. The i-Lynx offers hospitals a cost
effective method of both capture of the assay results, as well as
connectivity to Point of Care Software systems, providing necessary
information for both quality control and billing.

In addition to exhibiting the Cardiac Status™ line of products,
Spectral will be further demonstrating the EAA™ Endotoxin Activity
Assay, for use in risk stratifying critically ill patients for the
development of severe sepsis.

"We have been very pleased with customer response to the strip assay
reader, the i-Lynx," stated Dr. Paul Walker, President and CEO of
Spectral. "Both existing, as well as new customers realize its value and
we expect to reach our target for placements for this quarter."

"In addition, we are encouraged by developments in the early adopter
program for the Endotoxin Activity Assay. Interest in measuring the
EAA™ in critical illness is evident in numerous institutions focused
on organ transplantation, cardiac surgery, burns and patients in end
stage renal failure" continued Dr. Walker.

Spectral is a developer of innovative technologies for comprehensive
disease management. Spectral provides accurate and timely information to
clinicians enabling the early initiation of appropriate and targeted
therapy. Current products are rapid format tests measuring markers of
myocardial infarction (Cardiac STATus®). New products include rapid
diagnostics for sepsis (the Endotoxin Activity Assay). Spectral
manufactures the EAA™ and Cardiac STATus®. Spectral's common shares
are listed on The Toronto Stock Exchange: SDI.

Information in this news release that is not current or historical
factual information may constitute forward-looking information within
the meaning of securities laws. Implicit in this information,
particularly in respect of the completion of the proposed offering, the
future outlook of Spectral and anticipated events or results, are
assumptions based on beliefs of Spectral's senior management as well as
information currently available to it. While these assumptions were
considered reasonable by Spectral at the time of preparation, they may
prove to be incorrect. Readers are cautioned that actual results are
subject to a number of risks and uncertainties, including the
availability of funds and resources to pursue R&D projects, the
successful and timely completion of clinical studies, the ability of
Spectral to take advantage of business opportunities in the biomedical
industry, the granting of necessary approvals by regulatory authorities
as well as general economic, market and business conditions, and could
differ materially from what is currently expected.

SEDAR

Filer Profile Number: 00002006

-30-

Contact Information

  • FOR FURTHER INFORMATION PLEASE CONTACT:
    Spectral Diagnostics Inc.
    Dr. Paul Walker
    Chief Executive Officer
    (416) 626-3233